| Symbol | XCUR |
|---|---|
| Name | EXICURE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2430 N. HALSTED STREET,SUITE 410, CHICAGO, Illinois, 60614, United States |
| Telephone | +1 847 673-1700 |
| Fax | — |
| — | |
| Website | https://www.exicuretx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001698530 |
| Description | Exicure Inc is a clinical-stage biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology. Additional info from NASDAQ: |
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
Read moreExicure HiTron Inc. 🟢 acquired 623.3K shares of EXICURE, INC. (XCUR) at $4.50 ($2.8M) Transaction Date: Jun 23, 2026 | Filing ID: 000009
Read moreNew Form SCHEDULE 13D/A - EXICURE, INC. <b>Filed:</b> 2026-07-17 <b>AccNo:</b> 0002046701-26-000008 <b>Size:</b> 13 KB
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.
Read moreExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Delinquent. New value: Normal.
Read moreNASDAQ symbol attribute type Financial_Status was changed. Previous value: Delinquent. New value: Normal.
Read moreNASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Delinquent.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03684785 | Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients… | Phase1 | Advanced or Metastatic Merkel Cell Carcinoma | Terminated | 2018-12-13 | 2022-03-30 | ClinicalTrials.gov |
| NCT03086278 | A Study of AST-008 in Healthy Subjects | Phase1 | Healthy Volunteer Study | Completed | 2017-10-20 | 2018-08-16 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| AST-008 | Other | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT03086278 |
| Cemiplimab | Other | Phase PHASE1 | Advanced or Metastatic Merkel Cell Carcinoma | TERMINATED | NCT03684785 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced or Metastatic Merkel Cell Carcinoma | TERMINATED | NCT03684785 |
| Cavrotolimod | Other | Phase PHASE1 | Advanced or Metastatic Merkel Cell Carcinoma | TERMINATED | NCT03684785 |
| Cemiplimab | BIOLOGICAL | Phase PHASE1 | Advanced or Metastatic Merkel Cell Carcinoma | TERMINATED | NCT03684785 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE1 | Advanced or Metastatic Merkel Cell Carcinoma | TERMINATED | NCT03684785 |
| Cavrotolimod | DRUG | Phase PHASE1 | Advanced or Metastatic Merkel Cell Carcinoma | TERMINATED | NCT03684785 |
| AST-008 | DRUG | Phase PHASE1 | Healthy Volunteer Study | COMPLETED | NCT03086278 |